Treatment with Albendazole for Intestinal Disease Due to Enterocytozoon bieneusi in Patients with AIDS
Abstract
To determine the efficacy and safety of albendazole for treatment of intestinal microsporidosis due to Enterocytozoon bieneusi, 29 patients with AIDS were studied. All had chronic diarrhea, weight loss, and evidence of malabsorption. After 1 month of treatment with albendazole (400 mg orally twice a day), the mean number of bowel movements decreased from 7.0 to 3.8 stools/day (P < .0001) and the mean weight gain was 0.56 kg (P = .259). Albendazole at this dose did not clear E. bieneusi on follow-up small-bowel biopsies, but ultrastructural studies revealed an apparent decrease in parasite burden in 2 patients and an increased proportion of dividing plasmodia in 5 patients. There were no significant adverse events associated with this dose of albendazole. A formal double-blind placebo-controlled study using higher doses has recently been approved and will soon be underway (AIDS Clinical Trial Group protocol 207).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
E. bieneusi infection was not successfully cured using albendazole (800 mg daily for 28 days), with parasites not completely cleared in small-bowel biopsies of the patients.
“However, E. bieneusi infection was not successfully cured using albendazole (800 mg daily for 28 days), with parasites not completely cleared in small-bowel biopsies of the patients [299–302].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [300]
Cites
Liew, F. Y., Li, Y., & Millott, S. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.12.4306 · Cited by 522 · see citing works
Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha
Doherty, G. M., Lange, J. R., Langstein, H. N., Alexander, H. R., Buresh, C. M., & Norton, J. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.5.1666 · Cited by 300 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update
Chai, J.-Y., Jung, B.-K., & Hong, S.-J. (2021) · The Korean Journal of Parasitology · doi:10.3347/kjp.2021.59.3.189 · Cited by 286 · see citing works
Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence
Katiyar, S. K., Gordon, V. R., McLaughlin, G. L., & Edlind, T. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2086 · Cited by 217 · see citing works
Activity of Benzimidazoles against Cryptosporidiosis in Neonatal BALB/c Mice
Fayer, R., & Fetterer, R. (1995) · The Journal of Parasitology · doi:10.2307/3283980 · Cited by 31 · see citing works
- Authors
- Dieterich, D. T., Lew, E. A., Kotler, D. P., Poles, M. A., & Orenstein, J. M.
- Affiliations
- NYU Langone Health (US)
- Corresponding author
- Dieterich, D. T.
- ORCID
- Poles, M. A.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-01-01
- Volume
- 169
- Issue
- 1
- Pages
- 178-183
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W1997924001
- Cited by
- 170
- References
- 2
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 1 · 2018: 3 · 2017: 2 · 2015: 3 · 2014: 5 · 2013: 1 · 2012: 3
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Parasitic Infections and Diagnostics
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Health Sciences › Medicine › Epidemiology › Pneumocystis jirovecii pneumonia detection and treatment
- Keywords
- albendazole, Enterocytozoon bieneusi, intestinal microsporidiosis, AIDS, chronic diarrhea, malabsorption, weight loss, treatment efficacy, drug safety, infection intensity, ultrastructural analysis
- MeSH terms
- Administration, Oral, Adult, Chronic Disease, Diarrhea, Drug Evaluation, Feces, Follow-Up Studies, Humans, Intestinal Diseases, Parasitic, Male, Middle Aged, Nausea, Weight Gain, Albendazole, Microsporidiosis, Treatment Outcome, AIDS-Related Opportunistic Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
